Hepatitis C Virus disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

HCV MCID: HPT073 MIFTS: 70	Hepatitis C Virus (HCV) Categories: Cancer diseases, Gastrointestinal diseases, Genetic diseases, Immune diseases, Infectious diseases, Liver diseases, Nephrological diseases, Oral diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Hepatitis C Virus

MalaCards integrated aliases for Hepatitis C Virus:

Name: Hepatitis C Virus ⁵⁷ ⁷⁵

Hepatitis C Virus Infection, Response to Therapy of ⁵⁷ ²⁸ ⁵

Hepatitis C Virus, Susceptibility to ⁵⁷ ²⁸ ⁵

Hepatitis C Virus, Response to Therapy of ⁵⁷

Hepatitis C Virus, Resistance to ⁵⁷

Resistance to Hepatitis C Virus ⁵

Hcv, Susceptibility to ⁵⁷

Hcv ⁵⁷

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases Infectious diseases
Anatomical: Immune diseases Liver diseases Gastrointestinal diseases Nephrological diseases Oral diseases

See all MalaCards categories (disease lists)

External Ids:

OMIM® ⁵⁷ 609532

Sources

Summaries for Hepatitis C Virus

OMIM®: ⁵⁷ HCV, which is principally transmitted by blood, infects about 3% of the world's population. HCV infection causes acute hepatitis, which is self-resolving in 20 to 50% of cases but does not confer permanent immunity. In 50 to 80% of cases, HCV infection becomes chronic and results in chronic hepatitis, cirrhosis, and hepatocellular carcinoma. As a result, HCV infection is a leading killer worldwide and the most common cause of liver failure in the U.S. HCV is opportunistic in individuals infected with human immunodeficiency virus (HIV; see 609423), approximately 25% of whom are coinfected with HCV. HCV infection is also associated with cryoglobulinemia (see 123550), a B-lymphocyte proliferative disorder (Pawlotsky, 2004; Chisari (2005); Pileri et al., 1998). (609532) (Updated 08-Dec-2022)

MalaCards based summary: Hepatitis C Virus, also known as hepatitis c virus infection, response to therapy of, is related to hepatitis c and viral infectious disease. An important gene associated with Hepatitis C Virus is IFNG (Interferon Gamma), and among its related pathways/superpathways are Cytokine Signaling in Immune system and Overview of interferons-mediated signaling pathway. The drugs Ezetimibe and Pentoxifylline have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and bone marrow, and related phenotypes are Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection and Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection

Wikipedia: ⁷⁵ The hepatitis C virus (HCV) is a small (55-65 nm in size), enveloped, positive-sense single-stranded RNA... more...

Sources

Related Diseases for Hepatitis C Virus

Diseases in the Hepatitis family:

Hepatitis C Virus	Hepatitis a
Hepatitis C	Viral Hepatitis
Hepatitis B	Hepatitis D
Autoimmune Hepatitis	Hepatitis E
Autoimmune Hepatitis Type 2	Autoimmune Hepatitis Type 1

Diseases related to Hepatitis C Virus via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1322)

#	Related Disease	Score	Top Affiliating Genes
1	hepatitis c	33.1	SCARB1 PSMA7 PI4KA IFNL4 IFNG IFITM3
2	viral infectious disease	33.0	IFNG EIF2AK2 CLEC4M CCR5
3	hepatitis	32.7	SLC3A2 SCARB1 PSMA7 PI4KA IFITM3 EIF2AK2
4	hepatitis b	32.5	PSMA7 IFNG EIF2AK2 DDX3X
5	acquired immunodeficiency syndrome	31.5	IFNG CCR5 APOE
6	stomatitis	31.5	IFNG IFITM3 EIF2AK2
7	human immunodeficiency virus infectious disease	31.1	IFNG CLEC4M CCR5
8	influenza	30.9	IFNG IFITM3 EIF2AK2 CLEC4M
9	herpes zoster	30.9	IFNG CCR5 APOE
10	west nile virus	30.9	SPCS1 IFITM3 CLEC4M CCR5
11	ebola hemorrhagic fever	30.9	IFITM3 CLEC4M CCR5
12	encephalitis	30.7	SPCS1 DDX3X CLEC4M CCR5
13	neuritis	30.2	IFNG CCR5 APOE
14	west nile fever	30.2	CLEC4M CCR5
15	hepatocellular carcinoma	11.6
16	recurrent hepatitis c virus induced liver disease in liver transplant recipients	11.6
17	cryoglobulinemia, familial mixed	11.5
18	liver cirrhosis	11.5
19	polyarteritis nodosa	11.3
20	immune deficiency disease	11.3
21	liver disease	11.3
22	splenic marginal zone lymphoma	11.3
23	cryoglobulinemia	11.3
24	zinc-responsive necrolytic acral erythema	11.3
25	nodal marginal zone b-cell lymphoma	11.3
26	immunotactoid glomerulopathy	11.2
27	fibrillary glomerulonephritis	11.2
28	non-alcoholic fatty liver disease	11.2
29	gianotti crosti syndrome	11.2
30	immunotactoid or fibrillary glomerulopathy	11.2
31	viral hepatitis	11.2
32	vasculitis	11.1
33	glomerulonephritis	11.1
34	lymphoma, hodgkin, classic	11.1
35	lymphoma	11.1
36	human immunodeficiency virus type 1	11.0
37	type 2 diabetes mellitus	11.0
38	lichen planus	11.0
39	end stage renal disease	11.0
40	hemophilia	11.0
41	lymphoproliferative syndrome	11.0
42	fatty liver disease 1	11.0
43	membranoproliferative glomerulonephritis	11.0
44	b-cell lymphoma	11.0
45	primary agammaglobulinemia	11.0
46	hepatitis a	11.0
47	chronic kidney disease	11.0
48	alcohol use disorder	11.0
49	sjogren syndrome	10.9
50	autoimmune hepatitis	10.9

Graphical network of the top 20 diseases related to Hepatitis C Virus:

Sources

Symptoms & Phenotypes for Hepatitis C Virus

Clinical features from OMIM®:

609532 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	no effect	GR00402-S-1	10.13	ACY3 APOE CCR5 CLDN6 CLDN9 CLEC4M
2	no effect	GR00402-S-2	10.13	ACY3 APOE CCR5 CLDN6 CLEC4M DDX3X
3	Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection	GR00233-A-1	8.85	HM13
4	Increased JFH-1 genotype 2a Hepatitis C virus (HCV) infection after viral supernatant infection	GR00233-A-3	8.65	IFITM3

MGI Mouse Phenotypes related to Hepatitis C Virus:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	digestive/alimentary	MP:0005381	9.5	APOE CCR5 CLEC4M HM13 IFNG PI4KA
2	mortality/aging	MP:0010768	9.44	APOE CCR5 CLDN6 CLEC4M DDX3X EIF2AK2

Sources

Drugs & Therapeutics for Hepatitis C Virus

Drugs for Hepatitis C Virus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 249)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Ezetimibe

Approved

Phase 4

163222-33-1

150311

Pentoxifylline

Approved, Investigational

Phase 4

6493-05-6

4740

Amantadine

Approved

Phase 4

768-94-5

2130

Dopamine

Approved

Phase 4

62-31-7, 51-61-6

681

Diamorphine

Approved, Illicit, Investigational

Phase 4

561-27-3

5462328

Metformin

Approved

Phase 4

1115-70-4, 657-24-9

4091

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Chloroquine

Approved, Investigational, Vet_approved

Phase 4

54-05-7

2719

Colchicine

Approved

Phase 4

64-86-8

2833 6167

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Hyaluronic acid

Approved, Vet_approved

Phase 4

9004-61-9

53477741

Iron

Approved

Phase 4

7439-89-6

29936

Racivir

Approved, Investigational

Phase 4

143491-57-0, 143491-54-7

60877

Prednisolone phosphate

Approved, Vet_approved

Phase 4

302-25-0

Prednisolone acetate

Approved, Vet_approved

Phase 4

52-21-1

Prednisolone

Approved, Vet_approved

Phase 4

50-24-8

4894 5755

Methylprednisolone hemisuccinate

Approved

Phase 4

2921-57-5

1875

Methylprednisolone

Approved, Vet_approved

Phase 4

83-43-2

4159 6741

Lamivudine

Approved, Investigational

Phase 4

134678-17-4

60825

Nelfinavir

Approved

Phase 4

159989-64-7

64143

Zidovudine

Approved

Phase 4

30516-87-1

35370

Didanosine

Approved

Phase 4

69655-05-6

50599

Fosamprenavir

Approved

Phase 4

226700-79-4

131536

Cobicistat

Approved

Phase 4

1004316-88-4

24950485 25151504

Elvitegravir

Approved

Phase 4

697761-98-1

23083982 5277135

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Maraviroc

Approved, Investigational

Phase 4

376348-65-1

3002977

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6, 202138-50-9

464205 6398764

Prednisolone hemisuccinate

Experimental

Phase 4

2920-86-7

4897

Neurotransmitter Agents

Phase 4

Antiparkinson Agents

Phase 4

Radiation-Protective Agents

Phase 4

Phosphodiesterase Inhibitors

Phase 4

Vasodilator Agents

Phase 4

Dopamine Agents

Phase 4

Detox adjuvant

Phase 4

Anti-Retroviral Agents

Phase 4

Anti-HIV Agents

Phase 4

Hypoglycemic Agents

Phase 4

Calcineurin Inhibitors

Phase 4

Antirheumatic Agents

Phase 4

Cyclosporins

Phase 4

Antifungal Agents

Phase 4

Immunosuppressive Agents

Phase 4

Dermatologic Agents

Phase 4

Interventional clinical trials:

(show top 50) (show all 653)

#	Name	Status	NCT ID	Phase	Drugs
1	Hepatitis C in Renal Transplant Recipients - Safety and Efficacy of a Conversion of Immunosuppression to High-dose Cyclosporine A and Its Impact on Hepatitis C Virus-replication, Parameters of Liver Function and Glucose Tolerance. An Open Label Trial.	Unknown status	NCT02108301	Phase 4	tacrolimus-cyclosporine A
2	A Phase IV, Single Arm, Open-Label Study to Determine the Efficacy and Safety of Ledipasvir/Sofosbuvir (LDV/SOF) in Treatment-Naive Alcoholic Subjects With Chronic Genotype 1 Hepatitis C Infection	Unknown status	NCT02759861	Phase 4	harvoni
3	An Open-Label Study to Evaluate Long-Term Outcomes With Ombitasvir-Paritaprevir-Ritonavir and Dasabuvir With or Without Ribavirin (RBV) in Fertile Women With Genotype 1 and 4 Chronic Hepatitis C Virus (HCV) Infection	Unknown status	NCT02950870	Phase 4	Ombitasvir-Paritaprevir-Ritonavir;Dasabuvir;Ribavirin
4	Understanding HCV Reinfection Rates in an Incarcerated Population After Cure With Interferon Free HCV Treatment: A Pilot Project	Unknown status	NCT02460133	Phase 4	Paritaprevir;Ritonavir;Dasabuvir;Ombitasvir;Ribavirin
5	Pilot Study of Ezetimibe for Chronic Hepatitis C Virus (HCV) Infection in Liver Transplant Candidates (EZE-2)	Unknown status	NCT02768545	Phase 4	Ezetimibe
6	Direct Observed Therapy With Ledipasvir/Sofosbuvir in Treatment-naïve Patients With Chronic Genotype 1 HCV (Hepatitis C Virus) Infection Receiving Opiate Substitution Therapy	Unknown status	NCT02638233	Phase 4	Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)
7	the Prevalence of Acute Kidney Injury in Patients With Chronic Hepatitis c Virus Receiving Sofuspovir Containing Direct Acting Antiviral Therapy	Unknown status	NCT04267458	Phase 4
8	Grazoprevir/Elbasvir for Treatment of Hepatitis C Virus Genotype 4 Post Kidney Transplant	Unknown status	NCT03359746	Phase 4	Grazoprevir/Elbasvir
9	Effect Of Interferon-Free Direct Acting Antiviral Agents For Treatment Of Hepatitis C Virus Patients On The Normal Kidney	Unknown status	NCT03296930	Phase 4	Sofosbuvir 400 MG Oral Tablet,;Ombitasvir/paritaprevir/ritonavir
10	Efficacy of Pentoxyfylline Addition to a Treatment Scheme Based on Interferon Alpha and Ribavirin on Hepatitis C Virus Coinfected HIV Patients, Considering Interleukin 28B Polymorphism rs12979860	Unknown status	NCT02008214	Phase 4	Pentoxifylline;Placebo
11	Randomized, Multi-Center, Partially Placebo-Controlled Phase IV-Study to Compare Efficacy and Tolerability of 48-Week Combined Therapy With Peginterferon Alfa-2a, Ribavirin and Amantadine Sulphate Versus Placebo in Untreated Patients With Chronic Hepatitis C Virus-Genotype-1-Infection	Unknown status	NCT00127777	Phase 4	Amantadine sulphate (in addition to standard treatment)
12	Toward Elimination of Hepatitis C Virus (HCV): A Pilot Study Combining HCV and Addiction Treatment of Young Suburban Heroin Users (SHU) That Addresses Barriers to Care	Unknown status	NCT03364725	Phase 4	Glecaprevir-pibrentasvir
13	Efficacy and Safety of a Hansenula-derived Pegylated Interferon α2a (Reiferon Retard®) in Treatment of Patients With Chronic Hepatitis C Virus Infection: A National Multi-center Phase IV Open Label Non-Randomized Trial	Unknown status	NCT01649245	Phase 4	Reiferon retard
14	Generic Velpatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Hepatitis C Virus in Patients Coinfected With Human Immunodeficiency Virus	Completed	NCT03250910	Phase 4	Sofosbuvir and Velpatasvir;Ribavirin
15	A Study of the Antiviral Activity of Metformin as an Anti-Hepatitis C Virus Agent in Patients With Chronic Hepatitis C Virus Infection	Completed	NCT02972723	Phase 4	Metformin
16	A Phase 4, Multicenter, Open Label Study to Investigate the Efficacy and Safety of an All Oral Combination of Sofosbuvir+Ribavirin in Genotype 2 HCV-infected U.S. Veterans With Cirrhosis VALOR-HCV: Veterans Affairs alL Oral Regimen of SOF+RBV in GT2 HCV	Completed	NCT02128542	Phase 4	Sofosbuvir;RBV
17	Randomized Controlled Open Label Trial of Peg Alpha 2a Interferon and Adjusted-dose of Ribavirin vs. Standard Therapy in the Treatment of Naive Chronic Hepatitis C Patients Infected With Genotype 4	Completed	NCT01686789	Phase 4	Pegylated interferon alpha-2a
18	"Pharmacoepidemiological Evaluation of Autophagy Inhibition in Treatment of HCV Patients Resistant to Standard Therapy. Pilot Study"	Completed	NCT02058173	Phase 4	150 mg/daily chloroquine compare to placebo for 12 week;Chloroquine;placebo
19	Phase IV Study of Long Term Peg-Intron for Patients Who Have Failed to Respond to Rebetron/Interferon With Advanced Fibrosis and Cirrhosis Secondary to Hepatitis C- The Copilot Trial	Completed	NCT00179413	Phase 4	PEG -Intron;Colchicine
20	A Multicenter Study Evaluating the Efficacy and Safety of 12 Weeks Versus 24 Weeks Peginterferon Alfa-2a 40KD Combination Therapy With Ribavirin in Interferon Naïve Patients With Chronic Hepatitis C Genotype 2 or 3 Infection	Completed	NCT00143000	Phase 4	Peginterferon alfa-2a 40KD and Ribavirin
21	Concentration-Controlled Ribavirin for the Treatment of Patients With Chronic Hepatitis C Virus Infection	Completed	NCT01097395	Phase 4	ribavirin
22	A Multi-Site, Open-Label, Partially-Randomized Trial of the Efficacy and Safety of Fixed Dose Elbasvir/Grazoprevir (EBR/GZR) Based Regimens in French Subjects With Chronic Hepatitis C Virus (HCV) Genotype 4 Infection	Completed	NCT03111108	Phase 4	EBR/GZR (50 mg/100 mg) FDC
23	Improvement of the Surveillance and Control of Liver Disease and Complication Due to Chronic Hepatitis C: Project A) Antiviral Drugs Use, Efficacy, Safety and Costs; Project B) Kinetics of Virological Response.	Completed	NCT01195181	Phase 4	peginterferon plus ribavirin
24	Randomized Study on the Efficacy and Safety of Pegylated Interferon and Ribavirin in Hepatitis C Virus Infection After Liver Transplantation	Completed	NCT00383864	Phase 4	Pegylated interferon and ribavirin
25	A Randomized Trial Comparing a Short Course Versus Standard Treatment in Patients With Chronic Hepatitis C Virus Infection	Completed	NCT00502970	Phase 4	16 weeks Interferon Tiw with Ribavirin;24 weeks Interferon
26	Analysis of Gene Expression of PBMC in the Hepatitis C Virus Genotype 1b-infected Patients During Peg-interferon-α Plus Ribavirin Combination Therapy	Completed	NCT00680173	Phase 4	pegylated interferon alpha 2a and plus ribavirin
27	A Multi-Center, Open-Label Study of Glecaprevir/Pibrentasvir to Treat Recipients of Transplanted Kidneys From Deceased Donors With Hepatitis C Virus	Completed	NCT03781726	Phase 4	glecaprevir/pibrentasvir treatment
28	A Pilot Study to Assess the Feasibility of Hepatitis C Virus (HCV) Treatment as Prevention With Interferon-free Direct Acting Antivirals (DAAs) in the Prison Setting	Completed	NCT02064049	Phase 4	Sofosbuvir/velpatasvir
29	An Open-Label, Proof of Concept Study To Evaluate the Efficacy and Justification Of OBV/PTV/r and DSV In Adults With Chronic Hepatitis C Virus (HCV) Infection Genotype 2K/1B- NINJA Study	Completed	NCT03050905	Phase 4	VEKIRAX;EXVIERA
30	Randomized Clinical Trial to Assess the Effectiveness of Sofosbuvir in Combination With Daclatasvir or Simeprevir for 12 Weeks in Non-cirrhotic Subjects Infected With Chronic Hepatitis C Virus (HCV) Genotype 1 (TNT-1 Study)	Completed	NCT02624063	Phase 4	Daclatasvir + Sofosbuvir;Simeprevir + Sofosbuvir
31	Treatment of Acute Hepatitis C Virus in HIV Co-Infection	Completed	NCT00845676	Phase 4	Pegylated interferon alfa-2a + Ribavirin
32	Management of Hepatitis C Virus (HCV) Infection in Pregnant Women With Opioid Use Disorder (OUD): the Potential of an Integrated Medical Home Model: Phase IV Trial of Sofosbuvir/Velpatasvir (SOF/VEL) in Postpartum Women With Chronic HCV	Completed	NCT03057847	Phase 4	Sofosbuvir/Velpatasvir
33	Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Genotype 1-infected Patients in Taiwan	Completed	NCT00495131	Phase 4	Pegylated interferon alfa-2a plus ribavirin
34	Evaluation of the Benefit of Antithymocyte Induction Therapy on Hepatic Fibrosis in de Novo Hepatitis C Virus Liver Transplant Patients.	Completed	NCT00538265	Phase 4	tacrolimus;tacrolimus, ATG;ATG+mycophénolate mofétil+tacrolimus
35	Treatment of Acute Hepatitis C Virus Infection in Injection Drug Users With Pegylated Interferon for 24 Weeks	Completed	NCT00194480	Phase 4	Pegylated Interferon
36	A Phase IV Open-label, Multicentre, International Trial of Paritaprevir/Ritonavir, Ombitasvir, Dasabuvir ±Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection and Recent Injection Drug Use or Receiving Opioid Substitution Therapy	Completed	NCT02498015	Phase 4	"3D" regimen;"3D" regimen with ribavirin
37	A Phase IV, Multisite Study of the Treatment of Chronic Hepatitis C Virus Infection Genotype 1 in a Real World Large Health Maintenance Organization: An Evaluation of Real World Sustained Virological Response and Patient Reported Outcomes	Completed	NCT02461745	Phase 4	ombitasvir, paritaprevir/r, dasabuvir + ribavirin;ombitasvir, paritaprevir/r, dasabuvir
38	Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis	Completed	NCT03420300	Phase 4	EBR/GZR
39	Pegylated Interferon Alfa-2a Plus Ribavirin for Patients With Chronic Hepatitis c Virus on Opioid Pharmacotherapy: Virological and Psychological Outcomes	Completed	NCT01120795	Phase 4	Pegylated interferon and ribavirin
40	A Phase Iv Single-Arm Open-Label Non-Randomized Study To Evaluate The Safety And Pharmacokinetics Of Nelfinavir (Viracept, A430) 1250mg Twice Daily (250mg Or 625mg Forms) With Lamivudine/Zidovudine (Combivir) Background Therapy In Hiv/Hepatitis C Virus (Hcv) Co-Infected Subjects With Hepatic Dysfunction.	Completed	NCT00141284	Phase 4	nelfinavir 1,250 mg twice daily;Zidovudine 300 mg twice daily;Lamivudine 150 mg twice daily
41	Efficacy and Safety Study of Sofosbuvir Containing Regimens in Subjects With Chronic Hepatitis C Virus Genotype 2 Infection	Completed	NCT02482077	Phase 4	SOF+RBV;SOF+DCV;LDV/SOF
42	TEN Switch - An Observational Phase IV Study to Evaluate the Safety and Efficacy of Substituting Tenofovir for Didanosine in Virologically Controlled HIV-infected Patients Co-infected With Hepatitis C Virus.	Completed	NCT00358696	Phase 4	tenofovir
43	Evaluation of Liver Fibrosis by Serum Hyalornic Acid Measurement in β-Thalassemic Children Infected With Hepatitis C Virus Before and After Direct-Acting Antiviral Therapy	Completed	NCT03961828	Phase 4	Ledipasvir 90 MG / Sofosbuvir 400 MG [Harvoni]
44	Randomized, Controlled, Open Label, Pilot Study to Evaluate Fosamprenavir Activity on Genotype 1 Hepatitis C Virus (HCV) Infection Evolution in Human Immunodeficiency Virus (HIV) Co-infected Subjects With Antiretroviral Treatment Including Fosamprenavir	Completed	NCT01222611	Phase 4	Fosamprenavir
45	Treatment of Recently Acquired Hepatitis C Virus Infection	Completed	NCT01336010	Phase 4	Peginterferon alfa-2a;Ribavirin
46	Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis	Completed	NCT02874066	Phase 4	PTV/r/OBV/DSV
47	Sofosbuvir, Ribavirin, for the Treatment of Chronic Hepatitis C Virus Genotype 1 in HIV-Coinfected Patients Receiving Fixed Dose Co-formulation Emtricitabine/ Tenofovir/Cobicistat/Elvitegravir: A Pilot Study	Completed	NCT02220868	Phase 4	Sofosbuvir, Ribavirin, and Stribild
48	A Prospective, Single-center, Open-label, Pilot Study to Investigate the Effect of Switching to Certican® in Viremia of Hepatitis C Virus in Adult Renal Allograft Recipients.	Completed	NCT01469884	Phase 4	Everolimus;Cyclosporine;Tacrolimus
49	A Pilot Study to Evaluate Anti-Hepatitis C Virus Effect of Maraviroc in Patients Co-infected With Human Immunodeficiency Virus (HIV) and Hepatitis C	Completed	NCT02881762	Phase 4	Maraviroc
50	Pharmacist-led Hepatitis C Diagnosis and Rapid Management - in Community	Recruiting	NCT04322981	Phase 4

Search NIH Clinical Center for Hepatitis C Virus

Sources

Genetic Tests for Hepatitis C Virus

Genetic tests related to Hepatitis C Virus:

#	Genetic test	Affiliating Genes
1	Hepatitis C Virus, Susceptibility to ²⁸	CCR5 IFNG IFNL3
2	Hepatitis C Virus Infection, Response to Therapy of ²⁸

Sources

Anatomical Context for Hepatitis C Virus

Organs/tissues related to Hepatitis C Virus:

MalaCards : Liver, Kidney, Bone Marrow, T Cells, Whole Blood, B Cells, Thyroid

Sources

Publications for Hepatitis C Virus

Articles related to Hepatitis C Virus:

(show top 50) (show all 30043)

#	Title	Authors	PMID	Year
1	A functional SNP of interferon-gamma gene is important for interferon-alpha-induced and spontaneous recovery from hepatitis C virus infection. ⁶² ⁵⁷ ⁵	Huang Y...Liang TJ	17215375	2007
2	The CCR5-delta32 mutation: impact on disease outcome in individuals with hepatitis C infection from a single source. ⁵⁷ ⁵	Goulding C...Kelleher D	15863470	2005
3	MCPIP1 suppresses hepatitis C virus replication and negatively regulates virus-induced proinflammatory cytokine responses. ⁶² ⁵⁷	Lin RJ...Lin SY	25225661	2014
4	IPS-1 is essential for type III IFN production by hepatocytes and dendritic cells in response to hepatitis C virus infection. ⁶² ⁵⁷	Okamoto M...Seya T	24532585	2014
5	A class II phosphoinositide 3-kinase plays an indispensable role in hepatitis C virus replication. ⁶² ⁵⁷	Maehama T...Hanada K	24055031	2013
6	A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus. ⁶² ⁵⁷	Prokunina-Olsson L...O'Brien TR	23291588	2013
7	Identification of the Niemann-Pick C1-like 1 cholesterol absorption receptor as a new hepatitis C virus entry factor. ⁶² ⁵⁷	Sainz B...Uprichard SL	22231557	2012
8	EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy. ⁶² ⁵⁷	Lupberger J...Baumert TF	21516087	2011
9	Efficient hepatitis C virus particle formation requires diacylglycerol acyltransferase-1. ⁶² ⁵⁷	Herker E...Ott M	20935628	2010
10	Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. ⁶² ⁵⁷	Lanford RE...Orum H	19965718	2010
11	Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. ⁶² ⁵⁷	Thomas DL...Carrington M	19759533	2009
12	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. ⁶² ⁵⁷	Li Q...Elledge SJ	19717417	2009
13	Claudin-6 and claudin-9 function as additional coreceptors for hepatitis C virus. ⁶² ⁵⁷	Zheng A...Deng H	17804490	2007
14	Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry. ⁶² ⁵⁷	Evans MJ...Rice CM	17325668	2007
15	Apolipoprotein epsilon3 allele is associated with persistent hepatitis C virus infection. ⁶² ⁵⁷	Price DA...Donaldson PT	16299033	2006
16	Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. ⁶² ⁵⁷	Jopling CL...Sarnow P	16141076	2005
17	Adaptive immune responses in acute and chronic hepatitis C virus infection. ⁶² ⁵⁷	Bowen DG...Walker CM	16107834	2005
18	Evasion of intracellular host defence by hepatitis C virus. ⁶² ⁵⁷	Gale M...Foy EM	16107833	2005
19	Unscrambling hepatitis C virus-host interactions. ⁶² ⁵⁷	Chisari FV	16107831	2005
20	Unravelling hepatitis C virus replication from genome to function. ⁶² ⁵⁷	Lindenbach BD...Rice CM	16107832	2005
21	Identification of FBL2 as a geranylgeranylated cellular protein required for hepatitis C virus RNA replication. ⁶² ⁵⁷	Wang C...Ye J	15893726	2005
22	HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. ⁶² ⁵⁷	Khakoo SI...Carrington M	15297676	2004
23	Pathophysiology of hepatitis C virus infection and related liver disease. ⁶² ⁵⁷	Pawlotsky JM	15036326	2004
24	Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. ⁶² ⁵⁷	Foy E...Gale M	12702807	2003
25	Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. ⁶² ⁵⁷	Pohlmann S...McKeating JA	12634366	2003
26	L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. ⁶² ⁵⁷	Gardner JP...Olson WC	12676990	2003
27	The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. ⁶² ⁵⁷	Scarselli E...Vitelli A	12356718	2002
28	Subversion of cell signaling pathways by hepatitis C virus nonstructural 5A protein via interaction with Grb2 and P85 phosphatidylinositol 3-kinase. ⁶² ⁵⁷	He Y...Katze MG	12186904	2002
29	Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. ⁶² ⁵⁷	Tseng CT...Klimpel GR	11781364	2002
30	Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. ⁶² ⁵⁷	Crotta S...Valiante NM	11781363	2002
31	Identification of eIF2Bgamma and eIF2gamma as cofactors of hepatitis C virus internal ribosome entry site-mediated translation using a functional genomics approach. ⁶² ⁵⁷	Kruger M...Wong-Staal F	10900014	2000
32	Hepatitis C virus core protein-induced loss of LZIP function correlates with cellular transformation. ⁶² ⁵⁷	Jin DY...Jeang KT	10675342	2000
33	Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. ⁶² ⁵⁷	Thursz M...Thomas HC	10609818	1999
34	Hepatitis C virus and other flaviviridae viruses enter cells via low density lipoprotein receptor. ⁶² ⁵⁷	Agnello V...Zhang QX	10535997	1999
35	NS5A, a nonstructural protein of hepatitis C virus, binds growth factor receptor-bound protein 2 adaptor protein in a Src homology 3 domain/ligand-dependent manner and perturbs mitogenic signaling. ⁶² ⁵⁷	Tan SL...Katze MG	10318918	1999
36	Binding of hepatitis C virus to CD81. ⁶² ⁵⁷	Pileri P...Abrignani S	9794763	1998
37	Interferon-inducible protein SCOTIN interferes with HCV replication through the autolysosomal degradation of NS5A. ⁵⁷	Kim N...Yoo JY	26868272	2016
38	RACK1 controls IRES-mediated translation of viruses. ⁵⁷	Majzoub K...Imler JL	25416947	2014
39	IFN-λ receptor 1 expression is induced in chronic hepatitis C and correlates with the IFN-λ3 genotype and with nonresponsiveness to IFN-α therapies. ⁵⁷	Duong FH...Heim MH	24752298	2014
40	IL28B expression depends on a novel TT/-G polymorphism which improves HCV clearance prediction. ⁵⁷	Bibert S...Swiss Hepatitis C Cohort Study	23712427	2013
41	Variants in the ITPA gene protect against ribavirin-induced hemolytic anemia and decrease the need for ribavirin dose reduction. ⁵⁷	Thompson AJ...McHutchison JG	20547162	2010
42	ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. ⁵⁷	Fellay J...Goldstein DB	20173735	2010
43	IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. ⁵⁷	Suppiah V...George J	19749758	2009
44	Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. ⁵⁷	Tanaka Y...Mizokami M	19749757	2009
45	Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. ⁵⁷	Ge D...Goldstein DB	19684573	2009
46	Shared and distinct genetic variants in type 1 diabetes and celiac disease. ⁵	Smyth DJ...Todd JA	19073967	2008
47	Interaction between RANTES promoter variant and CCR5Delta32 favors recovery from hepatitis B. ⁵	Thio CL...Carrington M	19017985	2008
48	Altered CD45 expression in C77G carriers influences immune function and outcome of hepatitis C infection. ⁵⁷	Dawes R...Tchilian EZ	16505159	2006
49	CCR5 deficiency increases risk of symptomatic West Nile virus infection. ⁵	Glass WG...Murphy PM	16418398	2006
50	The case for selection at CCR5-Delta32. ⁵	Sabeti PC...Lander ES	16248677	2005

Sources

Genes for Hepatitis C Virus

Genes related to Hepatitis C Virus (3 elite genes):

(show top 50) (show all 54)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	IFNG	Interferon Gamma	Protein Coding	683.78	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Drug response ⁵ GeneCards inferred via : Publications (show sections)	17215375
2	CCR5	C-C Motif Chemokine Receptor 5	Protein Coding	683.38	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ Protective ⁵ GeneCards inferred via : Publications (show sections)	8751444 8756719 9207783 (more) 9140404 9132277 9055842 9466996 9511755 9600249 11517319 10520641 10615909 11081537 10803840 12874407 11403814 11403804 9585595 11781692 15744032 16216086 9768627 16248677 16418398 15863470 19017985 19073967 8639485
3	IFNL3	Interferon Lambda 3	Protein Coding	659.37	Molecular basis known ⁵⁷ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ GeneCards inferred via : Publications (show sections)
4	SCARB1	Scavenger Receptor Class B Member 1	Protein Coding	37.66	GeneCards inferred via : Publications Summaries Proteins Functions (show sections)
5	EIF2AK2	Eukaryotic Translation Initiation Factor 2 Alpha Kinase 2	Protein Coding	27.72	GeneCards inferred via : Publications Proteins Functions (show sections)
6	IFNL4	Interferon Lambda 4 (Gene/Pseudogene)	Protein Coding	27.4	GeneCards inferred via : Publications Summaries Functions (show sections)
7	APOE	Apolipoprotein E	Protein Coding	26.69	GeneCards inferred via : Publications Proteins Functions (show sections)
8	DDX3X	DEAD-Box Helicase 3 X-Linked	Protein Coding	26.67	GeneCards inferred via : Publications Proteins Functions (show sections)
9	HM13	Histocompatibility Minor 13	Protein Coding	26.62	GeneCards inferred via : Publications Summaries Functions (show sections)
10	CLDN6	Claudin 6	Protein Coding	26.61	GeneCards inferred via : Publications Summaries Functions (show sections)
11	CLDN9	Claudin 9	Protein Coding	26.47	GeneCards inferred via : Publications Summaries Functions (show sections)
12	TBC1D20	TBC1 Domain Family Member 20	Protein Coding	26.3	GeneCards inferred via : Publications Summaries Proteins (show sections)
13	PI4KA	Phosphatidylinositol 4-Kinase Alpha	Protein Coding	26.28	GeneCards inferred via : Publications Proteins Functions (show sections)
14	CLEC4M	C-Type Lectin Domain Family 4 Member M	Protein Coding	26.04	GeneCards inferred via : Publications Proteins Functions (show sections)
15	PNKD	PNKD Metallo-Beta-Lactamase Domain Containing	Protein Coding	25.96	GeneCards inferred via : Publications Gene name Functions (show sections)
16	PSMA7	Proteasome 20S Subunit Alpha 7	Protein Coding	25.93	GeneCards inferred via : Publications Summaries Functions (show sections)
17	SPCS1	Signal Peptidase Complex Subunit 1	Protein Coding	25.6	GeneCards inferred via : Publications Proteins Functions (show sections)
18	ACY3	Aminoacylase 3	Protein Coding	25.56	GeneCards inferred via : Publications Gene name Proteins (show sections)
19	IFITM3	Interferon Induced Transmembrane Protein 3	Protein Coding	25.54	GeneCards inferred via : Publications Proteins Functions (show sections)
20	SLC3A2	Solute Carrier Family 3 Member 2	Protein Coding	25.33	GeneCards inferred via : Publications Proteins Functions (show sections)
21	ATG5	Autophagy Related 5	Protein Coding	25.22	GeneCards inferred via : Publications Proteins Functions (show sections)
22	CHKA	Choline Kinase Alpha	Protein Coding	25.11	GeneCards inferred via : Publications Proteins Functions (show sections)
23	IFI27	Interferon Alpha Inducible Protein 27	Protein Coding	25.09	GeneCards inferred via : Publications Proteins Functions (show sections)
24	CCR5AS	CCR5 Antisense RNA	RNA Gene	25	Protective ⁵	8751444 8756719 9207783 (more) 9140404 9132277 9055842 9466996 9511755 9600249 11517319 10520641 10615909 11081537 10803840 12874407 11403814 11403804 9585595 11781692 15744032 16216086 9768627 16248677 16418398 15863470 19017985 19073967 8639485
25	SKP2	S-Phase Kinase Associated Protein 2	Protein Coding	24.88	GeneCards inferred via : Publications Proteins Functions (show sections)
26	GPS2	G Protein Pathway Suppressor 2	Protein Coding	24.75	GeneCards inferred via : Publications Proteins Functions (show sections)
27	NEURL3	Neuralized E3 Ubiquitin Protein Ligase 3	Protein Coding	24.59	GeneCards inferred via : Publications Proteins Functions (show sections)
28	AAK1	AP2 Associated Kinase 1	Protein Coding	24.51	GeneCards inferred via : Publications Proteins Functions (show sections)
29	CD81	CD81 Molecule	Protein Coding	18.84	GeneCards inferred via : Publications Functions (show sections)
30	CLDN1	Claudin 1	Protein Coding	17.95	GeneCards inferred via : Publications Functions (show sections)
31	GPT	Glutamic--Pyruvic Transaminase	Protein Coding	17.85	GeneCards inferred via : Publications Functions (show sections)
32	SSB	Small RNA Binding Exonuclease Protection Factor La	Protein Coding	17.53	GeneCards inferred via : Publications Summaries (show sections)
33	RIGI	RNA Sensor RIG-I	Protein Coding	17.35	GeneCards inferred via : Publications Functions (show sections)
34	IRF3	Interferon Regulatory Factor 3	Protein Coding	17.26	GeneCards inferred via : Publications Functions (show sections)
35	EGFR	Epidermal Growth Factor Receptor	Protein Coding	17.2	GeneCards inferred via : Publications Functions (show sections)
36	DEPDC5	DEP Domain Containing 5, GATOR1 Subcomplex Subunit	Protein Coding	17.15	GeneCards inferred via : Publications Summaries (show sections)
37	OCLN	Occludin	Protein Coding	17.11	GeneCards inferred via : Publications Functions (show sections)
38	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	17.08	GeneCards inferred via : Publications Functions (show sections)
39	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	17.05	GeneCards inferred via : Disorders Publications (show sections)
40	MAVS	Mitochondrial Antiviral Signaling Protein	Protein Coding	17.03	GeneCards inferred via : Publications Proteins (show sections)
41	PPIA	Peptidylprolyl Isomerase A	Protein Coding	16.99	GeneCards inferred via : Publications Functions (show sections)
42	EIF2B3	Eukaryotic Translation Initiation Factor 2B Subunit Gamma	Protein Coding	16.97	GeneCards inferred via : Publications Summaries (show sections)
43	RPL18A	Ribosomal Protein L18a	Protein Coding	16.97	GeneCards inferred via : Publications Summaries (show sections)
44	IFITM1	Interferon Induced Transmembrane Protein 1	Protein Coding	16.92	GeneCards inferred via : Publications Functions (show sections)
45	HAVCR2	Hepatitis A Virus Cellular Receptor 2	Protein Coding	16.88	GeneCards inferred via : Publications Expressions (show sections)
46	DDX60L	DExD/H-Box 60 Like	Protein Coding	16.84	GeneCards inferred via : Publications Summaries (show sections)
47	LDLR	Low Density Lipoprotein Receptor	Protein Coding	16.83	GeneCards inferred via : Publications Functions (show sections)
48	PLA2G12B	Phospholipase A2 Group XIIB	Protein Coding	16.67	GeneCards inferred via : Publications Summaries (show sections)
49	RILPL2	Rab Interacting Lysosomal Protein Like 2	Protein Coding	16.67	GeneCards inferred via : Publications Summaries (show sections)
50	FBXL2	F-Box And Leucine Rich Repeat Protein 2	Protein Coding	16.63	GeneCards inferred via : Publications Proteins (show sections)

Sources

Variations for Hepatitis C Virus

ClinVar genetic disease variations for Hepatitis C Virus:

⁵ (show all 11)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	CCR5, CCR5AS	NM_001394783.1(CCR5):c.554_585del (p.Ser185fs)	DEL	Protective	8184	rs333	GRCh37: 3:46414944-46414975 GRCh38: 3:46373453-46373484
2	IFNG	NM_000619.2(IFNG):c.-893C>G	SNV	Drug Response	14725	rs2069707	GRCh37: 12:68554288-68554288 GRCh38: 12:68160508-68160508
3	PTPRC	NM_002838.5(PTPRC):c.592C>A (p.Leu198Ile)	SNV	Uncertain Significance	1675115		GRCh37: 1:198672435-198672435 GRCh38: 1:198703306-198703306
4	KRT8	NM_002273.4(KRT8):c.160T>C (p.Tyr54His)	SNV	Uncertain Significance	14631	rs57749775	GRCh37: 12:53298606-53298606 GRCh38: 12:52904822-52904822
5	KRT8	NM_002273.4(KRT8):c.187A>G (p.Ile63Val)	SNV	Benign	66533	rs59536457	GRCh37: 12:53298579-53298579 GRCh38: 12:52904795-52904795
6	LOC106096416, KRT18, KRT8	NM_000224.3(KRT18):c.282C>T (p.Tyr94_Leu95=)	SNV	Not Provided	56166	rs386834224	GRCh37: 12:53343239-53343239 GRCh38: 12:52949455-52949455
7	LOC106096416, KRT18, KRT8	NM_000224.3(KRT18):c.134G>C (p.Arg45Pro)	SNV	Not Provided	56167	rs200221269	GRCh37: 12:53343091-53343091 GRCh38: 12:52949307-52949307
8	KRT8	NM_002273.4(KRT8):c.1340C>T (p.Ala447Val)	SNV	Not Provided	56169	rs386834223	GRCh37: 12:53291324-53291324 GRCh38: 12:52897540-52897540
9	LOC106096416, KRT18	NM_000224.3(KRT18):c.1230C>G (p.Thr410=)	SNV	Not Provided	56165	rs386834225	GRCh37: 12:53346563-53346563 GRCh38: 12:52952779-52952779
10	KRT8	NM_002273.4(KRT8):c.1033G>T (p.Ala345Ser)	SNV	Not Provided	56168	rs386834221	GRCh37: 12:53292632-53292632 GRCh38: 12:52898848-52898848
11	KRT8	NM_002273.4(KRT8):c.1412G>A (p.Gly471Glu)	SNV	Not Provided	56170	rs386834222	GRCh37: 12:53291252-53291252 GRCh38: 12:52897468-52897468

Cosmic variations for Hepatitis C Virus:

⁸ (show top 50) (show all 15388)

#	Cosmic Mut ID	Gene Symbol	COSMIC Disease Classification (Primary site, Site subtype, Primary histology, Histology subtype)	Mutation CDS	Mutation AA	GRCh38 Location	Conf
1	COSM97724722	ZXDB	liver,NS,carcinoma,hepatocellular carcinoma	c.1308C>A	p.D436E	23:57593356-57593356	6
2	COSM94430614	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	6
3	COSM94436083	ZSWIM1	liver,NS,carcinoma,hepatocellular carcinoma	c.1399A>C	p.S467R	20:45883991-45883991	6
4	COSM94063771	ZSCAN20	liver,NS,carcinoma,hepatocellular carcinoma	c.2314G>T	p.G772W	1:33494658-33494658	6
5	COSM88264637	ZRSR2	liver,NS,carcinoma,hepatocellular carcinoma	c.304G>T	p.E102*	23:15803788-15803788	6
6	COSM102741209	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	6
7	COSM131494492	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.1159A>G	p.M387V	22:29049340-29049340	6
8	COSM103081572	ZNRF3	liver,NS,carcinoma,hepatocellular carcinoma	c.859A>G	p.M287V	22:29049340-29049340	6
9	COSM95977701	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	6
10	COSM102131817	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	6
11	COSM95960776	ZNFX1	liver,NS,carcinoma,hepatocellular carcinoma	c.2580G>A	p.L860=	20:49257501-49257501	6
12	COSM113317148	ZNF853	liver,NS,carcinoma,hepatocellular carcinoma	c.1610G>T	p.G537V	7:6622601-6622601	6
13	COSM99592496	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.829T>A	p.F277I	19:36891962-36891962	6
14	COSM128686611	ZNF829	liver,NS,carcinoma,hepatocellular carcinoma	c.1072T>A	p.F358I	19:36891962-36891962	6
15	COSM123358576	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.691C>T	p.L231=	4:145885684-145885684	6
16	COSM123949383	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	6
17	COSM101741672	ZNF827	liver,NS,carcinoma,hepatocellular carcinoma	c.1741C>T	p.L581=	4:145885684-145885684	6
18	COSM86004822	ZNF653	liver,NS,carcinoma,hepatocellular carcinoma	c.1553A>C	p.H518P	19:11485673-11485673	6
19	COSM98561269	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
20	COSM142353152	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
21	COSM142221290	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
22	COSM99854658	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.156G>A	p.V52=	19:52002156-52002156	6
23	COSM139729931	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
24	COSM141470046	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
25	COSM141819438	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
26	COSM145038099	ZNF615	liver,NS,carcinoma,hepatocellular carcinoma	c.141G>A	p.V47=	19:52002156-52002156	6
27	COSM91868668	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.3900G>T	p.K1300N	19:30557161-30557161	6
28	COSM91880764	ZNF536	liver,NS,carcinoma,hepatocellular carcinoma	c.2171-78T>G	p.?	19:30534769-30534769	6
29	COSM140721836	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.2998+205G>A	p.?	18:25194955-25194955	6
30	COSM131506983	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	6
31	COSM94799980	ZNF521	liver,NS,carcinoma,hepatocellular carcinoma	c.3658+205G>A	p.?	18:25194955-25194955	6
32	COSM90582798	ZNF518B	liver,NS,carcinoma,hepatocellular carcinoma	c.1624G>T	p.E542*	4:10444705-10444705	6
33	COSM87577038	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.6715G>T	p.V2239L	9:106974156-106974156	6
34	COSM109096265	ZNF462	liver,NS,carcinoma,hepatocellular carcinoma	c.3433G>T	p.V1145L	9:106974156-106974156	6
35	COSM104985080	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.298+23785G>T	p.?	2:179745718-179745718	6
36	COSM104427909	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.20G>T	p.S7I	2:179745718-179745718	6
37	COSM151538615	ZNF385B	liver,NS,carcinoma,hepatocellular carcinoma	c.253+23785G>T	p.?	2:179745718-179745718	6
38	COSM127708351	ZNF345	liver,NS,carcinoma,hepatocellular carcinoma	c.47-856A>T	p.?	19:36891962-36891962	6
39	COSM135887725	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1168C>G	p.L390V	16:89734008-89734008	6
40	COSM84511025	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1219C>G	p.L407V	16:89734008-89734008	6
41	COSM111609487	ZNF276	liver,NS,carcinoma,hepatocellular carcinoma	c.1444C>G	p.L482V	16:89734008-89734008	6
42	COSM92353291	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.1010C>T	p.T337I	12:133010889-133010889	6
43	COSM130415812	ZNF26	liver,NS,carcinoma,hepatocellular carcinoma	c.950C>T	p.T317I	12:133010889-133010889	6
44	COSM88697750	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	6
45	COSM95253159	ZNF217	liver,NS,carcinoma,hepatocellular carcinoma	c.*194A>T	p.?	20:53569094-53569094	6
46	COSM94505616	ZMYND12	liver,NS,carcinoma,hepatocellular carcinoma	c.425-1G>T	p.?	1:42440026-42440026	6
47	COSM89943752	ZMYM4	liver,NS,carcinoma,hepatocellular carcinoma	c.86-8201G>T	p.?	1:35350724-35350724	6
48	COSM101398456	ZIC2	liver,NS,carcinoma,hepatocellular carcinoma	c.-18C>T	p.?	13:99982047-99982047	6
49	COSM113521587	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	6
50	COSM94679661	ZGPAT	liver,NS,carcinoma,hepatocellular carcinoma	c.*197C>A	p.?	20:63736116-63736116	6

Sources

Expression for Hepatitis C Virus

Genes differentially expressed in tissues of Hepatitis C Virus patients vs. healthy controls: ³⁵

#	Gene	Description	Tissue	Up/Dn	Fold Change (log2)
1	CXCL10	C-X-C motif chemokine ligand 10	Liver	+	4.26
2	CXCL11	C-X-C motif chemokine ligand 11	Liver	+	3.57
3	LINC02532	long intergenic non-protein coding RNA 2532	Liver	-	3.21
4	CXCL9	C-X-C motif chemokine ligand 9	Liver	+	3.07

Search GEO for disease gene expression data for Hepatitis C Virus.

Sources

Pathways for Hepatitis C Virus

Pathways related to Hepatitis C Virus according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	12.71	PSMA7 IFNL3 IFNG IFITM3 EIF2AK2 CCR5
2	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	11.53	IFNL4 IFNL3 IFNG IFITM3 CCR5
3	Selective expression of chemokine receptors during T-cell polarization ⁷⁴	10.13	IFNG CCR5

Sources

GO Terms for Hepatitis C Virus

Biological processes related to Hepatitis C Virus according to GeneCards Suite gene sharing:

(show all 11)

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	10.19	IFNL4 IFNL3 IFITM3 EIF2AK2 DDX3X CLEC4M
2	response to virus	GO:0009615	9.92	DDX3X EIF2AK2 IFITM3 IFNG
3	defense response to virus	GO:0051607	9.91	IFNL4 IFNL3 IFNG IFITM3 EIF2AK2
4	negative regulation of viral genome replication	GO:0045071	9.85	IFNL3 IFITM3 EIF2AK2
5	response to interferon-alpha	GO:0035455	9.78	IFITM3 EIF2AK2
6	cholesterol catabolic process	GO:0006707	9.76	SCARB1 APOE
7	high-density lipoprotein particle clearance	GO:0034384	9.71	SCARB1 APOE
8	cellular response to virus	GO:0098586	9.7	IFNL4 IFNL3 IFNG DDX3X
9	type III interferon-mediated signaling pathway	GO:0038196	9.61	IFNL4 IFNL3
10	virion assembly	GO:0019068	9.43	TBC1D20 SPCS1 APOE
11	viral entry into host cell	GO:0046718	9.4	SLC3A2 SCARB1 CLEC4M CLDN9 CLDN6 CCR5